Citadel Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-60,100
| Closed | -$1.08M | – | 11178 |
|
|
2020
Q2 | $1.08M | Sell |
60,100
-36,000
| -37% | -$501K | ﹤0.01% | 5698 |
|
|
2020
Q1 | $685K | Buy |
96,100
+41,200
| +75% | +$514K | ﹤0.01% | 5964 |
|
|
2019
Q4 | $1.31M | Buy |
54,900
+11,400
| +26% | +$314K | ﹤0.01% | 5102 |
|
|
2019
Q3 | $1.17M | Sell |
43,500
-19,800
| -31% | -$556K | ﹤0.01% | 5324 |
|
|
2019
Q2 | $1.72M | Buy |
63,300
+6,800
| +12% | +$213K | ﹤0.01% | 4784 |
|
|
2019
Q1 | $1.96M | Buy |
56,500
+18,900
| +50% | +$545K | ﹤0.01% | 4501 |
|
|
2018
Q4 | $734K | Sell |
37,600
-11,600
| -24% | -$239K | ﹤0.01% | 5790 |
|
|
2018
Q3 | $1.31M | Buy |
49,200
+4,500
| +10% | +$147K | ﹤0.01% | 5082 |
|
|
2018
Q2 | $1.69M | Sell |
44,700
-37,000
| -45% | -$1.42M | ﹤0.01% | 4368 |
|
|
2018
Q1 | $2.67M | Buy |
81,700
+39,600
| +94% | +$1.74M | ﹤0.01% | 3302 |
|
|
2017
Q4 | $2.05M | Buy |
42,100
+13,900
| +49% | +$703K | ﹤0.01% | 3597 |
|
|
2017
Q3 | $1.52M | Sell |
28,200
-3,900
| -12% | -$229K | ﹤0.01% | 3745 |
|
|
2017
Q2 | $1.8M | Buy |
32,100
+12,800
| +66% | +$513K | ﹤0.01% | 3309 |
|
|
2017
Q1 | $756K | Sell |
19,300
-9,200
| -32% | -$293K | ﹤0.01% | 4420 |
|
|
2016
Q4 | $640K | Buy |
28,500
+3,800
| +15% | +$74.2K | ﹤0.01% | 4528 |
|
|
2016
Q3 | $561K | Buy |
+24,700
| New | +$580K | ﹤0.01% | 4676 |
|
|
2016
Q2 | – | Sell |
-28,300
| Closed | -$577K | – | 7670 |
|
|
2016
Q1 | $577K | Buy |
28,300
+21,800
| +335% | +$692K | ﹤0.01% | 4210 |
|
|
2015
Q4 | $334K | Sell |
6,500
-300
| -4% | -$14.5K | ﹤0.01% | 5073 |
|
|
2015
Q3 | $290K | Buy |
6,800
+4,500
| +196% | +$217K | ﹤0.01% | 5616 |
|
|
2015
Q2 | $105K | Buy |
2,300
+1,700
| +283% | +$68.4K | ﹤0.01% | 7026 |
|
|
2015
Q1 | $23K | Buy |
+600
| New | +$20.6K | ﹤0.01% | 7832 |
|
Citadel Advisors's PTLA Position: Q3 2020 in Review
Citadel Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 68,854 shares — an estimated $1.24M sold.
Citadel Advisors first reported a position in PTLA in Q1 2014 and held it in 26 quarters. The position peaked at $58.9M in Q4 2015. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Citadel Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Citadel Advisors sold 68,854 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $1.24M.
- Citadel Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q1 2014 and held it in 26 quarters.
- Citadel Advisors's Portola Pharmaceuticals, Inc. position peaked at $58.9M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Citadel Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.